LINK Medical CEO Ola Gudmundsen and Michael Bodd from Serendipity Partners. Credit: Anders Horntvedt / LINK Medical.

North European full-service contract research organisation (CRO) LINK Medical has raised capital to fund further growth and invited Serendipity Partners as its part owner.

Currently, Serendipity holds 49% of the shares while LINK Medical CEO Dr Ola Gudmundsen still owns the rest of the shares. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Serendipity will offer growth capital to LINK Medical under this deal, which is chiefly structured as a share issue.

The companies intend to establish a robust Northern European CRO through the transaction.

LINK Medical has expanded steadily for nearly 27 years one step at a time. 

See Also:

The fundings obtained were used to expand LINK Medical, making the company one among the largest independent CROs in the Nordics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company chose to invite Serendipity as co-owner and long-term investor of LINK Medical to facilitate further expansion and offer new expertise to the CRO.

Serendipity’s Michael Bodd will serve as the board chairman in LINK Medical while Christopher Tangen will also be part of the board along with Ola Gudmundsen and Renee Amundsen.

Gudmundsen said: “As an investment fund specialising in life science, and with a base in Oslo, Serendipity Partners is the best partner for us. 

“More than just capital, they can add knowledge and competence, as Serendipity is run by medical doctors, pharmacists, and others with an extensive experience in pharma or biotech industries.” 

LINK Medical offers product development services to the pharmaceutical and medical device industries in Northern Europe. 

In February this year, the CRO signed a partnership agreement with Viedoc for a new collaboration programme to boost clinical trial efficiency.